Zimbabwe has declined a major US healthcare agreement worth 367 million US dollars (272 million pounds) over five years because of the United States' request for sensitive information.
The decision came to light after a government memo dated December was leaked, indicating that Head of State Emmerson Mnangagwa believed the arrangement was "unbalanced".
An official spokesman later explained that the United States was seeking genetic material for scientific study and commercial gain but was unwilling to guarantee the benefits from any future medical innovations.
"We will now turn to the challenging and unfortunate process of ending our health aid in Zimbabwe," said US ambassador to Zimbabwe Pamela Tremont in a statement.
Her embassy said the United States had furnished over $1.9bn as health assistance to Zimbabwe over the last two decades.
A medical body in Zimbabwe has called for more talks to reach a deal agreeable to all parties so the country's vital HIV treatment initiative can be sustained.
Broader Background
This development comes after a similar situation in Kenya, where a high court halted a related health funding agreement after legal challenges were raised about the safety of Kenyans' health data.
After returning to office last year, US President Donald Trump has slashed overseas assistance and shut down the key foreign aid agency.
USAID had administered assistance for the American government, but Trump claimed its spending was "inefficient" and his administration was pursuing government-to-government agreements to boost openness and responsibility.
According to statements, 16 African countries have so far signed these new agreements, representing more than $18.3bn in committed funds.
Details of the Rejected Agreement
The funds for Zimbabwe was intended to supported "tackling HIV/Aids, tuberculosis, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"We believe this partnership might have yielded significant benefits for Zimbabwean communities, especially the 1.2 million presently on HIV treatment via American-funded initiatives," Tremont added.
However, official spokesman Nick Mangwana said the arrangement was "unfair".
"Zimbabwe was being asked to surrender its biological resources and data indefinitely, with no corresponding guarantee of access to any medical innovations – such as new medicines or tests – that might be developed from that provided information," Mangwana explained.
"In essence, our country would provide the basic resources for medical research without any certainty that the resulting innovations would be available to our citizens should a new pandemic arise."
Sovereignty and International Frameworks
He also said that the US's withdrawal from the global health body and its push of bilateral health agreements were undermining frameworks already set up through the global organization.
The spokesperson cited its Pandemic Benefit-Sharing framework created to deal with future global health emergencies.
"This system is intended to guarantee that when a country contributes its information, the benefits – such as vaccines and treatments – are shared equitably, not monopolised solely by those with the funds to create them."
These objections regarding the US deal "are not meant as anti-American sentiment," Mangwana stressed.
"We encourage further discussions with our American counterparts on how future co-operation could be arranged in a way that honours the sovereignty and interests of each country."
Medical Community Response
The Zimbabwe College of Public Health Physicians (ZCPHP) stated it understood the official position, but urged that negotiations need to persist since a large portion of the country's HIV programmes depended on foreign aid.
"If technical issues arise, such as those involving information security or implementation frameworks, these can frequently be resolved via technical clarification and mutually agreed protections," it said.
The halted deal underscores the ongoing challenges between accepting crucial international aid and protecting a country's data in an ever more data-driven world.